Publication: Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
Program
KU-Authors
KU Authors
Co-Authors
Zwimpfer T.A., Ewald H., Jayawardana M., Appenzeller-Herzog C., Bizzarri N., Razumova Z., Kacperczyk-Bartnik J., Heinzelmann-Schwarz V., Friedlander M., Bowtell D.D.L., Garsed D.W.
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.
Source
Publisher
John Wiley and Sons Ltd
Subject
Medicine
Citation
Has Part
Source
Cochrane Database of Systematic Reviews
Book Series Title
Edition
DOI
10.1002/14651858.CD015896